Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$524M |
| 2 |
Meta Platforms (Facebook)
META
|
+$458M |
| 3 |
Otis Worldwide
OTIS
|
+$345M |
| 4 |
T-Mobile US
TMUS
|
+$307M |
| 5 |
AbbVie
ABBV
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$878M |
| 2 |
RTN
Raytheon Company
RTN
|
+$537M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$435M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
Accenture
ACN
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.72% |
| 2 | Healthcare | 14.52% |
| 3 | Financials | 12.98% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2076
Evolent Health
EVH
$346M
| $7.87M | ﹤0.01% |
1,105,509
+45,187
| +4% | +$303K |
|
2077
Nicolet Bankshares
NIC
$3.65B
| $7.83M | ﹤0.01% |
142,973
+3,966
| +3% | +$214K |
|
|
PRVB
2078
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $7.82M | ﹤0.01% |
554,159
+263,306
| +91% | +$3.32M |
|
2079
AnaptysBio
ANAB
$1.63B
| $7.81M | ﹤0.01% |
349,650
-7,937
| -2% | -$145K |
|
2080
Zentalis Pharmaceuticals
ZNTL
$352M
| $7.79M | ﹤0.01% |
+162,335
| New | +$6.23M |
|
2081
Bloom Energy
BE
$69B
| $7.79M | ﹤0.01% |
715,629
+186,482
| +35% | +$1.46M |
|
|
FLXN
2082
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $7.78M | ﹤0.01% |
591,672
+83,632
| +16% | +$867K |
|
|
CIR
2083
DELISTED
CIRCOR International, Inc
CIR
| $7.77M | ﹤0.01% |
305,039
+25,260
| +9% | +$393K |
|
2084
First Financial Corp
THFF
$979M
| $7.75M | ﹤0.01% |
210,356
+9,738
| +5% | +$331K |
|
2085
MGP Ingredients
MGPI
$379M
| $7.74M | ﹤0.01% |
210,854
+14,019
| +7% | +$501K |
|
2086
Amneal Pharmaceuticals
AMRX
$5.89B
| $7.74M | ﹤0.01% |
1,625,596
-80,966
| -5% | -$333K |
|
|
NWLI
2087
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $7.72M | ﹤0.01% |
37,993
+2,505
| +7% | +$477K |
|
2088
Agilysys
AGYS
$3.12B
| $7.71M | ﹤0.01% |
429,847
-16,212
| -4% | -$304K |
|
2089
Univest Financial
UVSP
$1.22B
| $7.69M | ﹤0.01% |
476,709
+25,533
| +6% | +$409K |
|
2090
Black Diamond Therapeutics
BDTX
$103M
| $7.66M | ﹤0.01% |
181,764
+91,367
| +101% | +$3.36M |
|
2091
Pacific Biosciences
PACB
$404M
| $7.66M | ﹤0.01% |
2,220,599
+70,238
| +3% | +$239K |
|
|
CMO
2092
DELISTED
Capstead Mortgage Corp.
CMO
| $7.66M | ﹤0.01% |
1,395,079
+64,484
| +5% | +$324K |
|
2093
Universal Insurance Holdings
UVE
$1.23B
| $7.66M | ﹤0.01% |
431,454
-26,943
| -6% | -$477K |
|
2094
Brookdale Senior Living
BKD
$3.45B
| $7.65M | ﹤0.01% |
2,594,126
-13,693
| -0.5% | -$44.3K |
|
2095
Ardelyx
ARDX
$1.21B
| $7.65M | ﹤0.01% |
1,105,538
+99,117
| +10% | +$689K |
|
2096
Icon
ICLR
$12.6B
| $7.63M | ﹤0.01% |
45,286
+2,367
| +6% | +$373K |
|
2097
Extreme Networks
EXTR
$3.43B
| $7.61M | ﹤0.01% |
1,754,228
+40,582
| +2% | +$143K |
|
2098
QuinStreet
QNST
$889M
| $7.57M | ﹤0.01% |
723,405
+36,907
| +5% | +$356K |
|
|
LGF.B
2099
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $7.55M | ﹤0.01% |
1,105,260
+6,246
| +0.6% | +$43.2K |
|
2100
Lennar Class B
LEN.B
$20.8B
| $7.55M | ﹤0.01% |
172,497
-22,494
| -12% | -$850K |
|
Similar funds
Geode Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Geode Capital Management held 4,219 positions worth $467B, up 22% from $384B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geode Capital Management's Q2 2020 filing shows 118 new, 2,550 increased, 1,055 reduced and 119 closed positions. Its largest new stake was Otis Worldwide: 6,650,358 shares worth $377M. The largest sale was Allergan plc, an estimated $878M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2020 buy was Otis Worldwide: 6,650,358 shares worth $377M.
- Geode Capital Management added most to Amazon in Q2 2020, an estimated $524M increase.
- Geode Capital Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $435M.
- Geode Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $878M.
- Geode Capital Management's ten largest holdings make up 23% of its $467B portfolio in Q2 2020.
- Geode Capital Management opened 118 new positions and closed 119 in Q2 2020.
- Geode Capital Management's portfolio value rose 22% quarter-over-quarter to $467B.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.